- Allergan Aesthetics announced Health Canada authorization for HArmonyCa with Lidocaine, a next-generation injectable that combines hyaluronic acid (HA) and calcium hydroxyapatite (CaHA) in a single treatment for facial soft tissue augmentation.
- The dual-action injectable is designed to provide an immediate lifting effect through HA while also stimulating the body’s natural collagen production using CaHA microspheres, with results lasting up to 18 months in some patients.
- The company highlighted growing demand for non-surgical aesthetic procedures that address facial volume loss, skin quality, and reduced skin tightness associated with aging.
- Clinical data showed that 91.6% of patients experienced improved facial appearance after treatment, while long-term follow-up findings demonstrated high patient satisfaction and willingness to repeat treatment. The product also demonstrated a manageable and self-limiting safety profile in post-marketing analysis.
Takeaways:
HArmonyCa with Lidocaine positions Allergan Aesthetics to capture more of Canada’s growing demand for longer-lasting, non-surgical facial rejuvenation by offering both immediate lift and collagen stimulation in one injectable.
Market-wise, the 18‑month durability, high satisfaction (over 90% of patients reporting improved appearance), and manageable safety profile give clinics a premium option to upsell beyond standard HA fillers, while Allergan strengthens its ecosystem around Juvéderm and Botox with a differentiated, higher-value hybrid biostimulator.
Source: CA Newswire
